

Covid-19, Delta Variant (B.1.617.2)

¹Padavi Yogesh M., ²Junagade Manish S., ³Yadav Pooja S.

Department of Pharmaceutical Quality Assurance,
M.G.V's Pharmacy College, Panchvati, Nashik, Maharashtra-422003, India

Abstract: The delta variant of COVID-19 known as B.1.617.2, Which was the main reason behind the second wave in India. The delta variant emerged after its first outbreak in 2020. This mutation in the spike protein that, this variant had increased rate of transmission and more severe infections. At the August 2021, the Delta variant has dominated the number of infections all over the world. In comparison to the original version, this variant of COVID-19 is extremely contagious (alpha). On 1st may 2021, India became the first country that recorded more than 40000 new cases within India in 24 hours. It became the most dominate virus in the world. In this review article, discuss the background of delta variant (B.1.617.2) with overview of Epidemiology of delta variant, Pathogenesis of delta variant, mutations of delta variant.

Keywords: COVID-19, SARS-CoV-2, Variants, Vaccines, Mutations, Delta Variant (B.1.617.2), Variant of Concern (VOC), Spike Protein Mutation

I. INTRODUCTION

The recently discovered novel virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-2), late Dec 31, 2019 in city of Wuhan, in the Hubei Province of China. And this is the biggest global pandemic. It is composed of a single-stranded positive ribonucleic acid (RNA) virus. Basically, it is a zoonotic virus that is transmitted from animals to humans, and this is the first virus to occur. This is known as a spillover event. It is known to be closely related to the coronavirus and bat populations identified by SARS-CoV-2. Two coronavirus RaTG13 and RmYN02 were discovered in bat's noses. Respectively homology was found that 96.2% and 93.3%, respectively with the SARS-CoV-2 virus.¹ The virus assigned temporary name 2019-nCoV. After that it was detected from infected individual's airway epithelial cells. Once it was established that the virus was related to SARS-CoV, Coronavirus Research Group (CSG) of the International Committee are designed the name SARS-CoV-2.

Throughout the pandemic, the SARS-CoV-2 spike protein is continuously mutating. Due to this mutation many variants discovered. Four of them variant are selected as variant of concern (VOC). This include variants B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) and P.1 (Gamma).² Delta (B.1.617.2) initially included as a variant of interest (VOI) According to World Health Organization (WHO). Various US authorities classify SARS-CoV-2 variants into three classes. Based on scientific proof. The Central Management Prevention (CDC) says that different classes of mutants include the first "variant of concern", the second "variant of concern" and the third "variant of concern". Update the report. A new variety known as the Delta plus B.1.617.2.1 and AY.1 has emerged from India in recent months and has spread to some other nations, including the United States (US). This is why the virus's viral spike protein has a substantial mutation in the delta version. It features a pointy aspect that gives it a crown-like form. The spike is shaped like a hook, and it searches for receptors in human cells to bind to. These spikes bind to a receptor called ACE2.³

According to WHO, this Delta known as b.1.617.2 is it more spreadable, more transmissible variant yet. because the delta variant, infection spreads by the replicating the genetic code of the virus after the spike protein unlocked the cell. Some keys mutation is make easier for spike attached to receptor in virus. like E484Q, L452R, and P614R. That means it infected and spread fastly and evade the immunity of body. According to an investigation, this variation arrived in the United States via England and Japan, with the first case being recorded in Washington state on May 3, 2021. However, research has discovered that AY.1 is more than just a Delta variant with an extra K417N mutation, and that it has a different mutation profile than B.1.617.2. This analysis focuses on delta variant, which has gotten a lot of attention because of its abrupt onset, quick spread, and serious clinical consequences. B.1.617.2 appears to be a more virulent mutant than earlier circulating variations WHO has updated the COVID 19 Weekly Epidemiological Report that Delta Variant has been recorded in 170 countries.⁵ According to study of china, Researcher published updated report in a preprint posted on 12 July, that virus was first visible four days. After exposure in patients with the Delta variation, compared to an average of six days in people with the original variant, implying that Delta replicates quicker. Delta infected patients had virus loads that were up to 1,260 times more than those infected with the original variant.

II. BACKGROUND

First time delta variant (B.1.617.2) detected in India in dec.2020. The second wave of covid-19 is the result of this. Covid-19's second phase focuses on the millions of lives lost between now and March 2021. After mid-March 2021, daily new cases in India jumped from 53 per million to lower than 200 per million. These figures reveal that the Indian government's healthcare system is under a great deal of pressure. A major humanitarian crisis, labelled a "national disaster, prompting appeals for international cooperation and alliance. As a result of the increase in hospitalizations, the healthcare infrastructure has crumbled. The scale of the collapse was such that there were severe shortages of oxygen, steroidal therapy drugs and diagnostic kits in several regions of India.³ The crematoriums and cemeteries were overflowing. Several preprints and investigative studies imply that the true death toll is much higher than the official figures. In addition to a lack of timely and strict preventative efforts directed by public health. On 1st may 2021, India became the first country that recorded >40000 new cases within India in 24 hours. Based on data obtained from the Ministry of Health and Family Welfare (MoHFW) on May 15. In 2021, there were 3,673,802 active cases, of which 20,432,898 were discharged and 266,207 deaths were reported.⁷ It became the world's most contagious virus. The delta variant is quickly spreading in India during the second wave of covid-19. As a result of the spreadability's high rate. It expanded to 78 different nations. By June

22, 2021, over 4500 variant sequences have been discovered in 78 countries. Data from the integrated disease surveillance program (IDSP) of the Indian government revealed that the 32% of patient of hospital and outdoor hospital were less than 30 years of age in the second wave. And 31% of first wave. Both the first and second wave among adults' 30-40 years still remains similar at 21%. Hospitalization for patients aged 20-39 increased from 23.7% to 25.5%, and for the age group 0-19 years increased from 4.2% to 5.8%. Results are also for more asymptomatic individuals. Delta had more shortness of breath on this second wave. The emergence and changed epidemiological features of the SARS-CoV-2 Delta variant (i.e., B.1.617.2 sub-lineage) may have contributed to the increase in case and death numbers in India during the second wave. Finally, we estimate the number of deaths that may have been averted if there had been an early countrywide intervention (such as a lockdown) during the second wave's commencement in March and April 2021.⁸ The identification and global spread of other VOCs were mirrored by the identification of B.1.1.7, B.1.351, and P.1 in India.³

B.1.617 in the United Kingdom (UK). 2 variant appeared in mid-April and accounted for 95 percent of the cases with delta variant above 1.1 million. And It recorded the largest number of delta variant patient in the United States (US) recently updated 2 April 2022, with over 1.4 million cases. Because of its capacity to invade the half immune system, the delta variant has quickly spread over 60 nations. Because it has a better capacity to replicate than the other progenitor strains. This variant had increased transmissibility and more severe infection. In the COVID pandemic, millions of lives were lost from COVID-19. The pandemic continues to have a tremendous impact on both physical and mental health care workers. They are not the only group that suffers from excessive stress due to this pandemic. normal people has illustrated psychiatric symptoms as well. The infection cases are continuing to increase despite vaccination efforts, pandemic restrictions and government-strict rules.

In Portugal, it was responsible for 70% of cases in Lisbon. It also leads to new record highs for COVID-19 patients and deaths in a number of Southeast Asian nations, including Myanmar, Indonesia, and Malaysia.⁹ B.1.617.2 is one of the 3 sub-lineage of the B.1.617 lineage. There are several spike mutations, including D614G, P681R, L452R, T19R, T478K, A222V, R158G, G142D; 156–157 deletion alongside the N- terminal site, and S2 substitution D950N. In the case of a few of the variants, a D614G mutation has been linked to larger viral loads in the inflamed respiratory tract, increased host infectivity, and maybe enhanced SARS-CoV-2 transmission performance. Because of the substitution on spike conformational diversity, it has been found to improve cleavage efficiency. P681R is located on the other side of the S1-S2 furin cleavage site. Similarly, mutation on the P681 position contributes to SARS-CoV-2 transmission and infection. On the opposite side, T478K and L452R found in B.1.617.2 had been related to vaccine break out and increases transmissibility. Several research confirmed that the L452R will increase infectivity by stabilizing the SARS-CoV-2 spike glycoprotein and human angiotensin-converting enzyme 2 (ACE2) receptor interaction. The more potent cell-virus attachment and increase infectivity end result because the L452R mutation reasons massive increments in loose energy on the receptor-binding area (RBD) and ACE2 binding complex. Other research also show that L452R mutant could evade the host leukocyte antigen (HLA)-24 limited cellular immunity, increase viral infectivity, and probably growth viral replication.¹⁰ The delta variant's transmissibility, infectivity, and immune evasion characteristics are all improved by these delta variant. In addition, B.1.617.2 has a higher risk of hospitalization and a higher severity of illness than B.1.1.7. Studies in the United Kingdom and Scotland have continuously shown that people infected with the delta variant in double rating as like as to be hospitalized as those infected with the alpha strain. Based on a cohort study in the United Kingdom where 74% of COVID19 patients were not vaccinated, patients infected with B.1.617.2 were hospitalized more than those infected within 14 days of testing for B.1.617.2. It was found that the risk of illness was high and the severity of the illness was high. Infected. 1.1.7 Variant. A Singapore study compared patients with B.1.1.7, B.1.351, and B.1.617.2, where B.1.617.2 could be oxygen demand, hospitalization or death in the intensive care unit (ICU). They also found that it was related to the high. The UK observed that B.1.617.2 had a higher secondary attack rate than B.1.1.7 for the both household and non-household contacts, as well as both travellers and non-travellers. In contrast, the 28-day mortality rate for B.1.617.2 remains low at 0.1% compared to B.1.1.7, which is 1.9%. Recently, there are also concerns about whether children are at high risk of becoming infected with B.1.617.2. The increase in cases in children seems most likely due to not being fully vaccinated yet. In addition, Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), said in a press conference that paediatric cases have increased and overall numbers have increased, but paediatric cases have not increased in severity.

III. SPIKE PROTEIN MUTATION

The SARS-CoV-2 is an envelope with fatty membrane, glycoproteins. With spherical shaped virus. That allow to attached with membrane of host cell, inject and entered in inter cell. Spike protein which located on SARS-CoV-2 Shell. It creates a liner chain of Approximate 1300 Amino acid this is help the virus enter through the epithelial membrane. These are attached with Angiotensin convert to enzyme-2. Which play important role in "Covid Infection" basically mutation is the change in DNA sequencing due to this error in the DNA copying to made using cell division. In delta variant changes in spike protein, which concern because they change in the structure of virus and biochemical characteristics. These changes facilitate the spike protein that attached to host cell and targeted to inhibit antibody. Selective sweeps in spike protein, that played a crucial role in evolution of SARS-CoV-2.¹¹

It shows that single mutation was responsible for transmission of the coronavirus from bats to humans.




Fig. 1 Structure of SARS-CoV-2 ¹¹

IV. PATHOGENESIS OF B.1.617.2

The delta variant of SARS-CoV-2 (B.1.617.2) compared to alpha strain (First covid-19 strain) has 23 mutations. Twelve of these mutations are in spike protein, showing in Fig. 1. The spike protein allows to bind with host cell that enter into the cell. Then spike protein is also the protein that target to eradication of the viruses. When virus entered in host cell that recognize by the immune system of the body. Then immune system produces the antibody for attach to this spike protein for eradication. The spike protein has two sub unit S1 and S2 are seen in fig.1, These are bind to ACE2 receptor, S2 aid in fuse and integration of virus into host Cell. The increasing mutated the spike protein with the increase difficulty. For the immune system. Identify them and attach antibodies for subsequent eradication of the virus. This new spike protein that circumvents the immune system allows for better binding with infects human cells and them more effectively.¹²




Fig. 2 SARS-CoV-2 Structure and binding schematic.¹²

(A) ACE-II Receptors on the surface of host cells. (B) Spike protein that attached to the ACEII receptor. (C) Virus fusion with the host cell membrane. Host cell proteases cleave spike proteins into S1 and S2 subunits. S1 is responsible for binding to ACE-II and S2 is responsible for virus fusion and viral entry. Upon S1 binding to ACE-II, subunits HR 1 and 2 form a 6helix bundle (6HB) to transport the virus. Particles close to the host cell that allow fusion and entry.

V. REASONS FOR MUTATIONS

Those viruses having ribonucleic acid as their genetic material those are frequently mutate Including SARS-CoV-2. When virus extremely spreading and causing illness. The possibility of virus mutating augments. Then more chances to virus spreading, replication and changes. Error in this copying process promote the mutation. Most viral mutations have minimal or no effect on the ability of the virus to exacerbate the disease. These are depending on where the mutations are located in virus genetic material and may affect the virus properties, like the immune escape, virulence and transmission. The assume that in rapid replication SARS-Cov-

2 are capable to make more than 1 billion copies of itself infecting an individual. And all this happened as mutation in genetic material of the virus.¹¹

VI. DELTA VARIANT MUTATION

Delta variant is most recorded transmissible variant yet. The mutation that found in the spike proteins and the spike gene mutation in B.1.617.2 variant include T19R, L452R, T478K, D614G, P681R and d960N with the position 157 and 158 at deletion. The spike protein mutations L452R and P681R are the most prominent. The L452R mutation replaces a leucine at position 452 with an arginine. According to one study, this enables the spike protein to bind to the ACE2 receptor with more affinity. The ACE2 receptor is a type of receptor found in the body a spike protein receptor presents in the human host in numerous cells of the body. SARS-ability CoV-2's to attach to this receptor. This could help to evade vaccine-stimulated antibodies. because the ACE2 receptor is linked to the spike protein with a greater affinity Other research has demonstrated that the L452R mutation can lead to. Other research has found that the L452R mutation allows the delta form to avoid being attacked by CD8 T lymphocytes, which are responsible for virus eradication. The P681R substitution is another significant mutation in the B.1.617.2 variation. At position 681, arginine replaces proline, and this mutation aids in the cleavage of the precursor spike protein into the activated versions of the spike protein known as S1 and S2. This would allow for virus superior fusion and integration into the host cell. When compared to Variations that aren't affected by this mutation.¹²

VII. EPIDEMIOLOGY OF THE DELTA VARIANT

According to the CDC delta variant are spread twice and more contagious than previous variant. The delta variant expanded across India after it first appeared in Maharashtra in late 2020. As of mid-April 2021, the delta variation was the most often reported variety in the country. Out of 604 SARS-CoV-2 genomes sequences reported to GISAID in Delhi, 385 were delta variant. The WHO Coronavirus infection and fatality rate profile (COVID-19) The second wave, which began in February 2021 and consisted of a higher percentage of the delta variety than the previous spike, began around February 2021. According to the American Society for Microbiology, this newer strain is responsible for 83 percent of cases in the United States and 90 percent in the United Kingdom. They even claim a 40–60 percent increase in transmissibility above the alpha variation, which was twice as infectious as the original Wuhan strain. On a qualitative level, the infection and fatality rates increase substantially rapidly, despite the fact that they happened in a much short time life. The first wave's peak instances were 5,001,049 vs. 5,703,208 in the second. The highest mortality rate in the first wave was 101,084 compared to 96,684 in the second; the first wave progressively increased until March before abruptly peaking from roughly October 2020 to February 2021. While the second wave accelerated from February 2021 until around June 2021, The delta variation has been shown to raise hospitalisation risk by 108 % on a quantitative basis. When compared to the original version, ICU admission was reduced by 235 % and mortality risk was reduced by 133 %. Travel from India and community transmission spread the delta variety to the UK. More than 75% of SARS-CoV-2 infections in England in May was connected to travel history and community transmission among individuals. The SARS-CoV-2 variant B.1.617 Delta emerged in February/ June 2021 in, Ontario, Canada after the emergence of VoC. That is, variant B1.1.17/alpha, B.1.351/beta, and P.1/ gamma with the N501Y mutation. By the end of April in the year 2021, According to a retrospective cohort analysis of 212,332 SARS-CoV-2 infected people, 77 percent were infected with N501y-positive VoCs, and 2.7 percent were possibly delta affected.¹²

In china, first delta infected case identified in Guangzhou, on May 21,2021. In Guangzhou, the delta variant quickly caused an outbreak. It all started with the first infected patient. On June 18,2021, a total of 167 persons reported. The number of people infected with the delta variation was counted Virus loads were reported in a survey. This was 1000 times higher in COVID-19 patients infected with the delta variant on the first positive PCR test than in COVID-19 patients infected with the clades 19A or 19B of SARS-CoV-2. It shows that delta variant has a greater pathogenicity rate in asymptomatic individuals during the rarely stages of infection. All VoCs, including the Delta variant have also been found in Canada, Africa, and the United States. Antigua and Barbuda, Brazil, Cayman Islands, and Barbuda Guatemala, Panama, French Guiana, Sint Maarten Guadeloupe, Uruguay, Argentina, Costa Rica, Chile Suriname, Curacao, Martinique, Puerto Rico, and the United States of America by August 20, 2021, the USA. Now the delta variant is the predominant variant among the cases with infected SARS-CoV-2. Estimated by and up to the November 25, 2021, there is a total 259,502,031 cases of COVID-19, including 5,183,003 deaths. The SARS CoV-2 variant is the delta variant which predominantly, accounts for more than 99% of the infection reported with increase in hospitalization and death cases. Delta variant is reported that more contagious as previous variants (alpha variant). Unvaccinated individuals are more at risk of infection and more probability to spreading infection.¹³ Individuals with pre-existing illnesses such chronic renal disease, cardiovascular disease, immunosuppression, chronic lung disease, and obesity predispose unvaccinated people to delta strain infection, according to the reference [14]. Other predisposing conditions for delta strain infection are sex, age, asthma and cancer. Reports that patient infected with delta strain are somewhat younger than patients infected with the alpha strain. Furthermore, there is a higher proportion of Asian patients infected with the delta variant in comparison to the alpha variant. This difference in uninfected of delta strain affected cases the comparison analysis of hospitalization and death rate outcome. Further studies are needed to assess death rate and the vaccine status.¹⁴

VIII. COMMON SYMPTOMS OF THE DELTA VARIANT

Delta mutants have common symptoms such as fever, shortness of breath, diarrhoea, cough, sore throat, and vomiting. It is part of the symptoms of the delta mutant. Loss of smell and taste, weakness, Myalgia's, and rhinorrhoea are some of the other symptoms. Current studies show that delta and alpha mutants have similar symptoms, but delta mutants are more viral and grow more in the respiratory tract. Loss of smell are less common, hearing loss, cough and gangrene due to worsening blood clots, according to a

research conducted in the United Kingdom. Resolving these conflicting data requires more research and case reports to determine if the delta variant actually causes different symptoms than the alpha variant.

People infected with the B.1.617.2, report symptoms that are slightly different from original variant of coronavirus. Cough, loss of smell, nausea, vomiting, and diarrhoea are less common in delta variants, but are still less commonly reported. The most common symptoms of delta mutations are sore cough, runny nose, short breathing, chills, fatigue, headache, loss of smell and fever.¹²

IX. COVID-19 VACCINES VERSUS THE VARIANTS

As of the May 2021 report, 91 COVID19 vaccine trials were in clinical development and 184 COVID19 vaccines were in preclinical development. Several facilities have been utilized in the development of these vaccines, those contain protein subunit, viral vector, RNA, inactivated virus, deoxyribonucleic acid (DNA), virus like particle and live attenuated. The FDA has approved three emergency vaccines in the United States, and data show that the mRNA vaccine provides adequate protection against COVID 19 variant B.1.1. 7.. The mRNA vaccines, Moderna and Pfizer were authorized in the United States before the identification of the South African strain (B.1.351 or 20H/501Y. V2) in the country. According to the latest research, these two vaccines induce less neutralizing antibodies than previous mutants. Janssen, Novavax, and AstraZeneca conducted studies using the predominant B.1.351 mutant in South Africa. These research showed the lower vaccine efficacy compared to other variants where this variant was not dominant. The vaccine efficacy of the Brazilian strain (B.1.1.28) has not yet been recorded. B.1.351 and P.1 consist of similar receptor-binding mutations, the vaccine efficacy against the P.1 mutant is assumed to be the same as B.1.351. Studies have shown that the vaccine is less effective against B.1.351 and may be less effective than the P.1 variant. Sinovac Biotech conducted a clinical trial showing that the corona vaccine prevented infection by the Brazilian P.1 strain by 50%. B.1.526 and B.1.525 show reduced vaccine efficacy. After research is need to study the efficacy of the current approved vaccines against the double mutant strain. According to the Indian Council of Medical Research Virology Lab, Bharat Biotech's "COVAXIN" vaccine is effective in neutralizing infections, with 78% of double mutants being transmitted.^{1,15}

X. CONCLUSION

Delta variant (B.1.617.2) variant are rapidly becoming the common variant of the COVID-19 pandemic. The delta strain is more contagious and it associated symptoms, and the social impacts of this virus. Delta variant (B.1.617.2) is the dominating all over the world due to its significantly increasing transmissibility. Delta variant are more transmissible and contagious than twice than original strain, alpha variant. variant have higher affinity to binding of ACE-2 to spike proteins. And decreasing the efficacy of vaccines against virus. Delta variant also have higher viral loads in infected individuals. Therefore, delta variant is more contagious. In India delta variant is the reason for second wave of covid-19. Delta variant (B.1.617.2) continuous emerges of new variants.

XI. ACKNOWLEDGMENT

The authors are thankful to Library Department of M.G. V's college of pharmacy, Panchavati (Nashik) for providing facilities for preparation of this review article.

REFERENCES

- [1] Vasireddy Deepa, Vanaparthi Rachana, Mohan Gishsa, Malayala Varun S., et. Al., Review of COVID-19 Variants and COVID-19 vaccine Efficacy: What the clinician should know? J Clin Med RES. 2021;13(6)317-325
- [2] Thye AY-K, Law JW-F, Pusparajah P, et al., Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. Biomedicine 2021; 9(10): 1303.
- [3] Thye AY-K, Loo Ke-Yan, Tan K-B Chene, Lau Jenny M-S, et. at., Insight into COVID-19 Delta variant (B.1.617.2). PMMB 2021, 4.1. 0000243
- [4] Dr. Alexandarl S., Ravishankar M., DR. Senthil Kumar, Dr. Jakkan Kannan. A Compressive review on Covid-19 delta variant, M. Ravisankar, et. Al., Int. J. of Pharmacology and Clin. Research Vol-5(2) 2021. page no. 83-85
- [5] Weekly epidemiological update on COVID-19 - 31 August 2021. 2021 31st August 2021. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19>
- [6] Vaughan A. Delta to dominate world, 2021, Elsevier.
- [7] Joseph RJ and Ser H-L, Stories from the East: COVID-19 Situation in India. Prog Microbes Mol Biol 2021; 4(1).
- [8] Salvatore Maxwell, Bhattacharyya Rupam, Purkayastha Soumik, Zimmermann Lauren, Ray Debashree, Hazra Aditi, Kleinsasser Michael, Mellan Thomas, Whittaker Charlie, Flaxman Seth, Bhatt. Samir, et. al., Resurgence of SARS-CoV-2 in India: Potential role of the B.1.617.2 (Delta) variant and delayed interventions. medRxiv 2021
- [9] Kwan JN, Loh HC, and Looi I, COVID-19 Vaccination during Pregnancy in Southeast Asia. Prog Microbes Mol Biol 2021; 4(1)
- [10] Motozono C, Toyoda M, Zahradnik J, et al., SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microb 2021; 29(7): 1124–1136.11.
- [11] Mohamed A. Hendaus, fatima A. Jomha, Delta variants of COVID-19: A simple explanation. Accepted: 19 September 2021 QATAR MEDICAL JOURNAL, VOL. 2021 / ART. 49.
- [12] Shiehzadegan S., Alaghemand Nazanin, Fox Michael and Venketaraman Vishwanath, Analysis of the Delta variant B.1.617.2 COVID-19 Clin.Paract.2021,11,77884
- [13] Naji.H. Epidemiology and Vaccine Efficacy of Delta Variant. European Journal of Medical and Health Sciences. (Ejmed) 2021.3.6.1162

- [14] Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis.* 2021.
- [15] Bernal J.L, Andrews Nick, Gower Charlotte, Gallagher Eileen, Simmons Ruth, Thelwall Simon, Stowe Julia N *Engl J Med* 2021; 385:585-94.

